Abstract: The invention relates to an aqueous dispersion of superparamagnetic iron-containing particles bearing ?-hydroxycarboxylic acids as stabilizer substances on their surface, said dispersion comprising N-methyl-D-glucamine (meglumine) and/or 2-amino-2-(hydroxymethyl)-1,3-propanediol (trometamol) and the content of free iron ions being lower than 1 mg of iron per liter. In a preferred embodiment the dispersion according to the invention may additionally include an iron-complexing agent. In another preferred embodiment the dispersion includes positively charged metal ions and/or compounds containing polyamino groups, which can be bound to substances having a therapeutic or diagnostic effect. The invention is also directed to a method of producing said dispersion, the use thereof as an MRT contrast medium as well as the use thereof as therapeutic agent, including the option of therapy follow-up using an imaging method.

Abstract: The invention relates to stabilized superparamagnetic particles which consist of superparamagnetic single domain particles and aggregations of superparamagnetic particles which are stabilized with aliphatic dicarboxylic or polycarboxylic acids and which contain charged ions of chemical elements on the surface of the small superparamagnetic single-domain particles and, optionally, an additional tissue binding substance or pharmacologically effective substance. The superparamagnetic particles consist of a mixture of small superparamagnetic single domain particles have a particle size ranging from 3 to 5 namometers and stable, degradable aggregations of small superparamagnetic particles having a particle size of 10-1000 nanometers, and are made of iron hydroxide, iron oxide hydrate, iron oxide, iron mixed oxide or iron.

Abstract: The invention relates to super-paramagnetic single domain particles with increased R1 relaxivity and with surface-stabilizer substances. The particles are characterized in that they consist of iron hydroxide, ferric hydrate, iron oxide, iron mixed oxide or iron; are between 1 and 10 nm in size, the mean particle diameter d50 being 2-4 nm; and have increased R1 relaxivity of between 2 and 50, the ratio of the relaxivities R2/R1 being less than 5. Stabilizer substances of special carboxylic acids are bound to the particle surfaces; these prevent aggregation and sedimentation under gravity or in a magnetic field. If necessary, the particles can also contain further known stabilizer substances and other pharmacological substances. The novel particles can be used for attacking tumors, boosting immunity, for cell fusion, gene transfer, or as contrasting agents in magnetic resonance diagnostics using magnetic fields where necessary.

Abstract: Superparamagnetic particles consist of superparamagnetic one-domain particles and aggregates of superparamagnetic one-domain particles to whose surfaces are bound inorganic and optionally organic substances optionally having further binding sites for coupling to tissue-specific binding substances, diagnostic or pharmacologically active substances. The superparamagnetic particles consist of a mixture of small superparamagnetic one-domain particles with a particle size from 3 to 50 nm and stable, degradable aggregates of small superparamagnetic one-domain particles with a particle size from 10 to 1000 nm. They are made of iron hydroxyide, iron oxide hydrate, iron oxides, iron mixed oxides or iron to the surface of which are bound silicate group containing substances among the orthosilicic acids and their condensation products and phosphate-group containing substances among the ortho- or metaphosphoric acids and their condensation products. These substances may have further binding sites.

Abstract: Superparamagnetic particles consist of superparamagnetic one-domain particles and aggregates of superparamagnetic one-domain particles to whose surfaces are bound organic substances optionally having further binding sites for coupling to tissue-specific binding substances, diagnostic or pharmacologically active substances. The superparamagnetic particles consist of a mixture of small superparamagnetic one-domain particles with a particle size from 3 to 50 nanometers and stable, degradable aggregates of small superparamagnetic one-domain particles with a particle size from 10 to 1000 nanometers.

Abstract: New superparamagnetic particles useful in medicine for destroying tumors, increasing immunity and diagnosing conditions are disclosed. For that purpose, very small superparamagnetic single-domain particles are aggregated and protected against further aggregation by chemical bonding of reactive stabilizer substances on the surface of the superparamagnetic particles. These new particles thus consist of stable, decomposable aggregates with a particle size in a range between 10 and 1000 nanometers and a defined behavior in a magnetic field.

Abstract: Magnetic liquid compositions are prepared from physiologically tolerated dispersions of stabilized superparamegnetic particles in water or aqueous salt solution and reactive stabilizer substances chemically bonded over phosphate, phosphonate or carboxylate groups to the surface of the superparamagnetic particles. The reactive stabilizer substances stabilize and chemically bond diagnostic and pharmacologically active substances.